

AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)

Principal Investigator: Dr. Tom Elliott **SubInvestigator:** Dr. Dale Clayton

Study coordinator & primary contact Marla Inducil MD, Hector Com MD, Glaiza Erfe MD, Alireza Moshiri, P: 604-628-7253 x 7011, minducil@bcdiabetes.ca; gerfe@bcdiabetes.ca, hcom@bcdiabetes.ca; amoshiri@bcdiabetes.ca

Summary: This study is intended to evaluate the efficacy, safety and tolerability of AZD6234 versus placebo (administered SC once weekly), for body weight management in participants with obesity or overweight with related comorbidities, when added to a stable regimen of incretin-based therapies.

Study location: [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Background & hypothesis: Endogenous amylin is a hormone co-secreted with insulin into the bloodstream by pancreatic β -cells. AZD6234 is a potent selective agonist of amylin receptors with a longer half-life and flatter PK profile. It is expected to complement incretin-based therapies and provide synergistic efficacy, greater long-term, high quality weight loss benefits, which could potentially be achieved via selective fat mass reduction and preservation of lean mass

Eligible Participants:

- ≥ 18 yrs of age
- BMI ≥ 30 kg/m² OR BMI ≥ 27 kg/m² with at least one weight-related comorbidity
- For T2DM A1c of $\geq 6.0\%$ - $\leq 9.0\%$ on diet and exercise or on oral Hypoglycemic agents; no insulin
- On any of the following: Injectable semaglutide (≥ 1.7 mg) once weekly; Oral semaglutide (25 mg) once daily; Liraglutide (3.0 mg) once daily; Tirzepatide (≥ 5 mg) once weekly

Treatment course and duration: The estimated maximum study follow-up for participants is approximately 74 weeks

Odds of receiving active drug are: 2:1 AZD6234:PBO

Procedure	Scr.	R	Titration Period *						Treatment Period (52 weeks)						SC [†]	Phone Visit ^{*,d}	EDV ^e	Details in Section	
			1	2	3	4	5	6	7	8	9	10	11	12					13
Visit	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15 ^f	-			
Week	-	1	2	3	4	5	9	13	17	21	25	29	41	53	69				
Day	up to -14	1	8	15	22	29	57	85	113	141	169	197	281	365	477				
Visit Window (Days)			± 3	± 3	± 3	± 3	± 3	± 3	± 5	± 5	± 5	± 5	± 5	± 5	± 5	± 3	± 3	± 3	
Fasted Visit		X							X			X			X	X			X

Study documents:

Short URL <https://bit.ly/43qlfjz>